Diffusion Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
11 mai 2020 16h11 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 11, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for...
Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS
05 mai 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
Inclusion in FDA’s Coronavirus Treatment Acceleration Program significantly shortens regulatory review cycles Simultaneous patient enrollment planned in both the U.S. and Eastern Europe to speed...
Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat Acute Respiratory Distress Syndrome in COVID-19
27 avr. 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
• Program to focus on enhanced blood oxygenation and reduction in patient progression to Intensive Care Units • Patient enrollment planned for both the U.S. and Eastern Europe ...
Diffusion Pharmaceuticals Evaluating TSC Against Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
01 avr. 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., April 01, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments...
Diffusion Pharmaceuticals Anticipates Enrollment in its Ambulance-based Stroke Trial Will be Slowed Due to the Impact of the Coronavirus
24 mars 2020 16h05 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., March 24, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments...
CORRECTION -- Diffusion Pharmaceuticals Reports 2019 Financial Results and Provides Business Update
18 mars 2020 18h34 HE
|
Diffusion Pharmaceuticals Inc.
$16.2 Million in Gross Proceeds RaisedNow Enrolling in Acute Stroke TrialGBM Data PresentedNew Board Appointment CHARLOTTESVILLE, Va., March 18, 2020 (GLOBE NEWSWIRE) -- In the news release issued...
Diffusion Pharmaceuticals Reports 2019 Financial Results and Provides Business Update
17 mars 2020 16h10 HE
|
Diffusion Pharmaceuticals Inc.
$16.2 Million in Gross Proceeds RaisedNow Enrolling in Acute Stroke TrialGBM Data PresentedNew Board Appointment CHARLOTTESVILLE, Va., March 17, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals...
Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. Gainer
12 mars 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., March 12, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments...
Diffusion Pharmaceuticals Receives European Patent Related Compositions of TSC
07 févr. 2020 08h30 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments...
Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr. to its Board of Directors
10 janv. 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”), a cutting-edge biotechnology company...